Saturday 17 October 2026
Export PLSE’s income statement to Excel — free account
Pulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022. In the quarter to June 2026, revenue grew 4,922.2%, EPS fell 28.6% and free cash flow fell 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
44.27
1.32
−2.90%
Follow PLSE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (78.49%) | (80.72%) | (74.45%) | (86.99%) |
+8 more TTM periods Free account |
|
| (67.90%) | (69.36%) | (64.12%) | (74.06%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(83.58%) | (119.59%) | (95.08%) | (84.43%) | |
Average Days of Receivables |
37.58 | 77.23 | 165.03 | 6.97 | |
Free Cash Flow per Share |
(0.89) | (0.82) | (0.81) | (0.72) | |
Free Cash Flow |
(61.39) | (55.50) | (54.44) | (48.77) | |
Capital Expenditures |
(0.29) | (0.30) | (0.31) | (0.26) | |
| Other line items | |||||
Cash ROIC |
(30.52%) | (41.23%) | (33.73%) | (25.96%) | |
Accounts Receivable Turnover |
18.66 | 8.99 | 4.11 | 20.68 | |
Accounts Payable Turnover |
0.42 | 0.46 | 0.50 | 0.49 | |
Inventory Turnover |
8.24 | 9.96 | 2.50 | 0.29 | |
Average Days of Payables |
874.52 | 857.67 | 915.63 | 946.01 | |
Days of Inventory on Hand |
72.88 | 63.99 | 44.84 | 18.11 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4,378.57% | 6,333.96% | 7,379.70% | 5,655.98% | |
Selling, General and Administrative Expense of Revenue |
2,629.45% | 4,162.94% | 5,285.31% | 4,363.61% | |
Share Based Compensation of Revenue |
1,474.43% | 2,383.83% | 3,540.76% | 2,961.83% | |
Operating CF/Net income |
0.76 | 0.74 | 0.74 | 0.65 | |
Depreciation/Fixed assets |
0.96 | 1.03 | 1.02 | 1.04 | |
Capex/Depreciation |
(0.28) | (0.29) | (0.29) | (0.24) | |
Revenue per Share |
0.02 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.88) | (0.81) | (0.80) | (0.72) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.24 | 0.41 | 0.52 | 0.33 |
Columns are period end dates